Quintiles Transnational has struck a deal to conduct 11 mid-stage cancer trials on six new therapies in development at Eisai in exchange for an unspecified array of milestone payments. Quintiles has been steadily building up its expertise in the oncology field, with 640 studies under its belt in the past nine years. Story